Wire Stories

Category Added in a WPeMatico Campaign

news_6

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene's anti-PD-1 antibody tislelizumab...

news_6

OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011

Covers therapeutic applications of OSE-127/S95011 through 2037 NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced...

news_6

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and...